Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-29
2011-11-01
Jarrell, Noble (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S478000
Reexamination Certificate
active
08048872
ABSTRACT:
The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
REFERENCES:
patent: 4303584 (1981-12-01), Pearce
patent: 4305878 (1981-12-01), Chu et al.
patent: 4307100 (1981-12-01), Langlois et al.
patent: 4347249 (1982-08-01), Potier et al.
patent: 5047528 (1991-09-01), Kutney et al.
patent: 6242457 (2001-06-01), Penco et al.
patent: RE37449 (2001-11-01), Kutney et al.
patent: 6365735 (2002-04-01), Rool
patent: 6555547 (2003-04-01), Pamukcu et al.
patent: 2005/0222190 (2005-10-01), Curd et al.
patent: 0 010 458 (1980-04-01), None
patent: WO 2005/055939 (2005-06-01), None
patent: WO 2005/055943 (2005-06-01), None
Jantzen and Robinson. Modern Pharmaceutics, 1996, p. 596.
Barnett et al. Journal of Medicinal Chemistry, 1978, 21(1), pp. 88-96.
Hussey et al. Journal of Pharmaceutical Sciences, 1976, 67 (9), 1319-20.
Cibotti, M.C. et al., “Monoclonal Antibodies to Bis-Indole Alkaloids ofCatharanthus roseusand Their Use in Enzyme-Linked Immuno-Sorbent-Assays,”Phytochemistry29:2109-2114, Pergamon Press (1990).
El-Sayed, A. et al., “CatharanthusAlkaloids, XXXVIII. Confirming Structural Evidence and Antineoplastic Activity of the Bisindole Alkaloids Leurosine-N′b-oxide (Pleurosine), Roseadine and Vindolicine fromCatharanthus roseus,” J. Nat. Prod. 46:517-527, American Society of Pharmacognosy (1983).
Hussey, R.L. and Newlon, W.M., “High-Performance Liquid Chromatographic and TLC Determinations of Desacetylvinblastine Amide (Vindesine) and Its Monosulfate Salt,”J. Pharm. Sci. 67:1319-1320, American Pharmaceutical Association (1978).
Mangeney, P. et al., “5′-Nor Anhydrovinblastine. Prototype of a New Class of Vinblastine Derivatives.”Tetrahedron 35:2175-2179, Pergamon Press (1979).
Mukhopadhyay, S. and Cordell, G.A., “CatharanthusAlkaloids. XXXV. Isolation of Leurosidine N′b-Oxide fromCatharanthus roseus,” J. Nat. Prod. 44:611-613, The American Society of Pharmacognosy (1981).
Spearman, M.E. et al., “Disposition of the Monoclonal Antibody-Vinca Alkaloid Conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 Rats and Rhesus Monkeys,”Drug Metab. Dispos. 15:640-647, The American Society for Pharmacology and Experimental Therapeutics (1987).
Thimmaiah, K.N. and Sethi, V.S., “Structural Investigations of the Products of Vincristine Sulfate Formed after in Vitro Incubation of the Alkaloid in Bile of Dogs,”Microchem. J 41:320-326, Academic Press, Inc. (1990).
International Search Report for International Patent Application No. PCT/US2007/004252, U.S. Patent and Trademark Office, Alexandria, Virginia, mailed Jun. 4, 2008.
Bickel, M.H., “The Pharmacology and Biochemistry of N-oxides,”Pharmacol. Rev. 21:325-355, The Williams & Wilkins Co. (1969).
Brown, J.M. and Wilson, W.R., “Exploiting Tumour Hypoxia in Cancer Treatment,”Nat. Rev. Cancer 4:437-447, Nature Pub. Group (2004).
Hadfield, J.A. et al., “Tubulin and microtubules as targets for anticancer drugs,”Progress in Cell Cycle Research 5:309-325, Plenum (2003).
Jehl, F. et al., “Pharmacokinetic and Preliminary Metabolic Fate of Navelbine in Humans as Determined by High Performance Liquid Chromatography,”Cancer Research 51:2073-2076, American Association for Cancer Research (1991).
Kuehne, M.E. et al., “The Syntheses of 16a′-homo-Leurosidine and 16a′-homo-Vinblastine. Generation of Atropisomers,”J. Org. Chem. 66:5317-5328, American Chemical Society (2001).
Maguire, M.H. and Csonka-Khalifah, L., “Vinca alkaloids inhibit conversion of arachidonic acid to thromboxane by human platelet microsomes: comparison with other microtubule-active drugs,”Biochem. Biophys. Acta 921:426-436, Elsevier Science Publishers B.V. (1987).
Morales-Rios, M.S. et al., “13C NMR Spectroscopy of Indole Derivatives,”Magnetic Resonance in Chemistry 25:377-396, John Wiley & Sons, Ltd. (1987).
Ragot, S. et al., “Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry,”J. Chromatography B 753:167-178, Elseivier Science B.V. (2001).
Supplementary European search report for European Patent Application No. 07751041.0, European Patent Office, Munich, Germany, mailed Apr. 13, 2010.
Wargin, W.A. and Lucas, V.S., “The Clinical Pharmacokinetics of Vinorelbine (Navelbine),”Seminars in Oncology 21:21-27, W. B. Saunders Company (1994).
Curd John G.
Goodwin Bradford
Henner W. David
Keana John F. W.
Lalani Alshad S.
Jarrell Noble
Stat of Oregon Acting by and Through The Oregon State Board of H
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Treatment of hyperproliferative diseases with vinca alkaloid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hyperproliferative diseases with vinca alkaloid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hyperproliferative diseases with vinca alkaloid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311096